Immunolocalization of ERK1/2 and p-AKT in normal endometrium, endometrial hyperplasia, and early and advanced stage endometrioid endometrial adenocancer and their prognostic significance in malignant group

Simple item page
dc.contributor.authorGungorduk, K
dc.contributor.authorErtas, IE
dc.contributor.authorSahbaz, A
dc.contributor.authorOzvural, S
dc.contributor.authorSarica, Y
dc.contributor.authorOzdemir, A
dc.contributor.authorSayhan, S
dc.contributor.authorGokcu, M
dc.contributor.authorYilmaz, B
dc.contributor.authorSanci, M
dc.contributor.authorInan, S
dc.contributor.authorHarma, M
dc.contributor.authorYildirim, Y
dc.date.accessioned2024-07-18T12:03:01Z
dc.date.available2024-07-18T12:03:01Z
dc.description.abstractObjective: To analyze the expression patterns of extracellular signal-regulated kinase (ERK1/2) and phosphorylated (p)-AKT in the tissues of non-pathologic endometrium, endometrial hyperplasia, and early and advanced stage endometrioid endometrial adenocancer using indirect immunohistochemistry, and also to investigate the effect of ERK1/2 and p-ART expression patterns on prognosis in endometrioid adenocancer. Study design: Immunolocalization of ERK1/2 and p-Ala was examined in six different types of endometrial tissues: proliferative endometrium (PE; n = 10, 11.2%), secretuar endometrium (SE; n = 10, 11.2%), simple hyperplasia (SH; n = 15,16.9%), complex hyperplasia (CH; n=3, 3.4%) and atypical complex hyperplasia (ACH; n = 10, 11.2%), which were obtained from endometrial biopsies, curettage materials, and hysterectomy specimens and classified as the benign group; and both early stage endometrioid (n = 21, 23.6%) and advanced stage endometrioid adenocancer (AC; n=20, 22.5%), which were obtained from complete surgical staging materials and classified as the malignant group. All specimens were fixed in 10% formalin and processed using routine paraffin protocols. Immunostaining intensities were evaluated as negative or weak (assigned as low expression) and moderate or strong (assigned as high expression). Results: In the malignant group, 23 of 41 patients (56.1%) had high ERK1/2 and p-AKT expression, whereas only three of 48 patients in the benign group (6.3%) had high ERK1/2 and p-ART expression (P < 0.0001 and P < 0.0001, respectively), p-ART expression was significantly higher in women with positive lymph nodes (OR 9.0; 95% CI: 1.2-100.0; P = 0.03). Higher expression of p-Ala was significantly associated with poor progression-free survival (PFS) and overall survival (OS). In contrast, ERK1/2 expression was not associated with PFS or OS. Conclusions ERK1/2 and p-ART can be useful in the differential diagnosis of benign vs. malignant endometrial lesions, as well as early vs. advanced stage endometrioid endometrial adenocancer. Additionally, higher p-ART expression could be used as a marker of poor prognosis in the management of patients with endometrioid endometrial adenocancer. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
dc.identifier.issn0301-2115
dc.identifier.other1872-7654
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/8843
dc.language.isoEnglish
dc.publisherELSEVIER
dc.subjectESTROGEN-RECEPTOR-ALPHA
dc.subjectSIGNALING PATHWAY
dc.subjectKINASE
dc.subjectCANCER
dc.subjectACTIVATION
dc.subjectCARCINOMA
dc.subjectPHOSPHORYLATION
dc.subjectPROLIFERATION
dc.subjectINHIBITION
dc.subjectSURVIVAL
dc.titleImmunolocalization of ERK1/2 and p-AKT in normal endometrium, endometrial hyperplasia, and early and advanced stage endometrioid endometrial adenocancer and their prognostic significance in malignant group
dc.typeArticle

Files

Collections

Web of Science Koleksiyonu